Granulocyte Colony-Stimulating Factor Improves Endothelial Progenitor Cell-Mediated Neovascularization in Mice with Chronic Kidney Disease.

chronic kidney disease endothelial progenitor cell granulocyte colony-stimulating factor neovascularization

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
25 Sep 2023
Historique:
received: 23 08 2023
revised: 13 09 2023
accepted: 20 09 2023
medline: 28 10 2023
pubmed: 28 10 2023
entrez: 28 10 2023
Statut: epublish

Résumé

Patients with chronic kidney disease (CKD) have a higher prevalence of peripheral arterial disease (PAD), and endothelial progenitor cells (EPCs) play a pivotal role. We examined the impact of granulocyte colony-stimulating factor (G-CSF) on EPC function in response to tissue ischemia. Eight-week-old male C57BL/6J male mice were divided into sham operation and subtotal nephrectomy (SNx) groups, received hindlimb ischemic operation after seven weeks, then randomly received G-CSF or PBS intervention for four weeks with weekly follow-ups. SNx mice had significantly reduced limb reperfusion, decreased plasma EPC mobilization, and impaired angiogenesis in ischemic hindlimbs compared to the control group. However, G-CSF increased IL-10 and reversed these adverse changes. Additionally, ischemia-associated protein expressions, including IL-10, phospho-STAT3, VEGF, and phospho-eNOS, were significantly downregulated in the ischemic hindlimbs of SNx mice versus control, but these trends were reversed by G-CSF. Furthermore, in cultured EPCs, G-CSF significantly attenuated the decrease in EPC function initiated by indoxyl sulfate through IL-10. Overall, we discovered that G-CSF can improve EPC angiogenic function through a hypoxia/IL-10 signaling cascade and impede neovascular growth in response to ischemia of SNx mice. Our results highlight G-CSF's potential to restore angiogenesis in CKD patients with PAD via EPC-based methods.

Identifiants

pubmed: 37896140
pii: pharmaceutics15102380
doi: 10.3390/pharmaceutics15102380
pmc: PMC10610103
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : National Science and Technology Council, Taiwan
ID : MOST 108-2314-B-303-006-MY3, and MOST 111-2314-B-303-017-MY3
Organisme : Taipei Tzu Chi Hospital
ID : TCRD-TPE-MOST-111-12 and TCRD-TPE-111-07
Organisme : Buddhist Tzu Chi Medical Foundation, Taiwan
ID : TCMFA 107-01-13(112), and TCMF-JCT 111-17

Références

Nat Med. 2004 Aug;10(8):858-64
pubmed: 15235597
Redox Biol. 2020 Feb;30:101433
pubmed: 31972507
Circulation. 2004 Aug 10;110(6):738-43
pubmed: 15262830
J Mol Cell Cardiol. 2004 Feb;36(2):233-9
pubmed: 14871551
Kidney Int. 2000 Jul;58(1):353-62
pubmed: 10886582
Lancet. 2003 Aug 30;362(9385):697-703
pubmed: 12957092
Int J Mol Sci. 2022 Jul 28;23(15):
pubmed: 35955492
Kidney Int. 2016 Mar;89(3):574-85
pubmed: 26880454
J Am Soc Nephrol. 2007 Feb;18(2):629-36
pubmed: 17215445
Kidney Int. 1999 Oct;56(4):1524-33
pubmed: 10504504
Heart. 2021 Nov;107(22):1835-1843
pubmed: 33985986
Int J Gen Med. 2021 Jul 23;14:3749-3759
pubmed: 34326661
J Am Soc Nephrol. 2012 Jul;23(7):1258-70
pubmed: 22626821
Ann N Y Acad Sci. 2001 Jun;938:36-45; discussion 45-7
pubmed: 11458524
J Immunol. 2016 Nov 1;197(9):3725-3734
pubmed: 27707998
Am J Kidney Dis. 1996 May;27(5):668-72
pubmed: 8629626
Clin J Am Soc Nephrol. 2009 Aug;4(8):1302-11
pubmed: 19541818
Angiogenesis. 2019 Feb;22(1):53-65
pubmed: 29987448
Health SA. 2023 Mar 31;28:2221
pubmed: 37064644
Trends Cardiovasc Med. 2005 May;15(4):152-7
pubmed: 16099380
Hum Immunol. 2021 Apr;82(4):309-314
pubmed: 33648804
J Pharmacol Sci. 2005 Sep;99(1):45-51
pubmed: 16127245
Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1179-84
pubmed: 19461050
FASEB J. 2013 Dec;27(12):4691-702
pubmed: 23964077
Front Immunol. 2018 Jun 18;9:1383
pubmed: 29967618
Angiogenesis. 2012 Sep;15(3):377-89
pubmed: 22467057
Nature. 2000 Sep 14;407(6801):242-8
pubmed: 11001067
Circ Res. 2000 Jun 23;86(12):1198-202
pubmed: 10864908
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):541-553
pubmed: 31996023
Hypertension. 2005 Mar;45(3):321-5
pubmed: 15655116
J Exp Med. 2001 May 7;193(9):1005-14
pubmed: 11342585
Atherosclerosis. 2010 Oct;212(2):426-35
pubmed: 20637466
J Immunol. 2004 Jan 1;172(1):567-76
pubmed: 14688368
EMBO J. 1999 Jul 15;18(14):3964-72
pubmed: 10406801

Auteurs

Shao-Yu Tang (SY)

Department of Medical Education, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan.

Yi-Chin Lee (YC)

Department of Physiology, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.

Chien-Wei Tseng (CW)

Department of Chinese Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan.
School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien 97004, Taiwan.

Po-Hsun Huang (PH)

Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.
Cardiovascular Research Center, School of Medicine, National Yang Ming Chiao Tung, Taipei 11221, Taiwan.
Divisions of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.

Ko-Lin Kuo (KL)

School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien 97004, Taiwan.
Division of Nephrology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan.
School of Medicine, Tzu Chi University, Hualien 97004, Taiwan.

Der-Cherng Tarng (DC)

Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 11221, Taiwan.
Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.

Classifications MeSH